

# Yi Hu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8477970/publications.pdf>

Version: 2024-02-01

26  
papers

699  
citations

623699

14  
h-index

580810

25  
g-index

27  
all docs

27  
docs citations

27  
times ranked

817  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel and Effective Therapeutic Regimens for <i>Helicobacter pylori</i> in an Era of Increasing Antibiotic Resistance. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 168.	3.9	115
2	<i>Helicobacter pylori</i> CagA promotes epithelial mesenchymal transition in gastric carcinogenesis via triggering oncogenic YAP pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 280.	8.6	102
3	Primary Antibiotic Resistance of <i>Helicobacter pylori</i> in China. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1146-1154.	2.3	77
4	Recent progress in <i>Helicobacter pylori</i> treatment. <i>Chinese Medical Journal</i> , 2020, 133, 335-343.	2.3	61
5	Inhibition of autophagy aggravates DNA damage response and gastric tumorigenesis via Rad51 ubiquitination in response to <i>H. pylori</i> infection. <i>Gut Microbes</i> , 2020, 11, 1567-1589.	9.8	41
6	Downregulation of tumor suppressor RACK1 by <i>Helicobacter pylori</i> infection promotes gastric carcinogenesis through the integrin $\beta$ 1/NF- $\kappa$ B signaling pathway. <i>Cancer Letters</i> , 2019, 450, 144-154.	7.2	39
7	Analysis of key genes and signaling pathways involved in <i>Helicobacter pylori</i> -associated gastric cancer based on The Cancer Genome Atlas database and RNA sequencing data. <i>Helicobacter</i> , 2018, 23, e12530.	3.5	31
8	Optimization of vonoprazan-amoxicillin dual therapy for eradicating <i>Helicobacter pylori</i> infection in China: A prospective, randomized clinical pilot study. <i>Helicobacter</i> , 2022, 27, e12896.	3.5	31
9	The Importance of Toll-like Receptors in NF- $\kappa$ B Signaling Pathway Activation by <i>Helicobacter pylori</i> Infection and the Regulators of this Response. <i>Helicobacter</i> , 2016, 21, 428-440.	3.5	30
10	Amoxicillin-vonoprazan dual therapy for <i>Helicobacter pylori</i> eradication: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1666-1672.	2.8	27
11	Therapeutic endoscopic retrograde cholangiopancreatography in a patient with situs inversus viscerum. <i>World Journal of Gastroenterology</i> , 2015, 21, 5744.	3.3	20
12	<i>Helicobacter pylori</i> promotes gastric epithelial cell survival through the PLK1/PI3K/Akt pathway. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5703-5713.	2.0	18
13	Diagnosis and treatment of <i>Helicobacter pylori</i> infections in children and elderly populations. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 243-251.	1.2	15
14	Caudal type homeoboxes as a driving force in <i>Helicobacter pylori</i> infection-induced gastric intestinal metaplasia. <i>Gut Microbes</i> , 2020, 12, 1809331.	9.8	14
15	Convergent dysbiosis of gastric mucosa and fluid microbiome during stomach carcinogenesis. <i>Gastric Cancer</i> , 2022, 25, 837-849.	5.3	14
16	The effect of antioxidants on <i>Helicobacter pylori</i> eradication: A systematic review with meta-analysis. <i>Helicobacter</i> , 2018, 23, e12535.	3.5	13
17	RACK1 Acts as a Potential Tumor Promoter in Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-8.	1.5	9
18	Impact factors that modulate gastric cancer risk in <i>Helicobacter pylori</i> -infected rodent models. <i>Helicobacter</i> , 2019, 24, e12580.	3.5	9

#	ARTICLE	IF	CITATIONS
19	Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for <i>Helicobacter pylori</i> Infection: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 844915.	2.6	8
20	Upregulation of oncogene Activin A receptor type I by <i>Helicobacter pylori</i> infection promotes gastric intestinal metaplasia via regulating CDX2. <i>Helicobacter</i> , 2021, 26, e12849.	3.5	7
21	Expression of c-Met and hepatocyte growth factor in various gastric pathologies and its association with <i>Helicobacter pylori</i> infection. <i>Oncology Letters</i> , 2017, 14, 6151-6155.	1.8	6
22	Establishment and Characterization of a Nude Mouse Model of Subcutaneously Implanted Tumors and Abdominal Metastasis in Gastric Cancer. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-6.	1.5	4
23	Reverse hybrid therapy for <i>Helicobacter pylori</i> eradication: A systematic review and meta-analysis. <i>Helicobacter</i> , 2021, 26, e12784.	3.5	4
24	Expression and prognostic significance of the DNA damage response pathway and autophagy markers in gastric cancer. <i>Neoplasia</i> , 2021, 68, 1310-1319.	1.6	2
25	Discovery and Validation of Novel Methylation Markers in <i>Helicobacter pylori</i> -Associated Gastric Cancer. <i>Disease Markers</i> , 2021, 2021, 1-11.	1.3	2
26	IDDF2021-ABS-0113...Upregulation of oncogene activin a receptor type i by helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2. , 2021, , .		0